6.48

3.57% -0.24

Pre-market: 6.64 0.16 +2.47%

Vir Biotechnology Inc (VIR)

Overview News Price History Option Chain Financials Why VIR Down? Discussions Forecast

Vir Biotechnology Inc stock is traded at $6.48, with a volume of 1.51M. It is down -3.57% in the last 24 hours and up +15.10% over the past month. Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Previous Close:

$6.72

Open:

$6.68

24h Volume:

1.51M

Relative Volume:

1.00

Market Cap:

$901.53M

Revenue:

$62.04M

Net Income/Loss:

$-533.34M

P/E Ratio:

-1.6531

EPS:

-3.92

Net Cash Flow:

$-473.07M

1W Performance:

-2.70%

1M Performance:

+15.10%

6M Performance:

+23.66%

1Y Performance:

-14.29%

1-Day Range:

$6.36

$6.70

1-Week Range:

$6.36

$6.97

52-Week Range:

$4.155

$14.45

Vir Biotechnology Inc Stock (VIR) Company Profile

Name

Vir Biotechnology Inc

Sector

Healthcare (1129)

Industry

Biotechnology (629)

Phone

415-906-4324

Address

1800 OWENS STREET, SAN FRANCISCO, CA

Employee

408

Twitter

@Vir_Biotech

Next Earnings Date

2024-10-31

Latest SEC Filings

VIR's Discussions on Twitter

Compare VIR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VIR Vir Biotechnology Inc	6.48	934.92M	62.04M	-533.34M	-473.07M	-3.92
VRTX Vertex Pharmaceuticals Inc	454.96	115.62B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	746.36	79.10B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	851.42	52.39B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	391.17	51.72B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	200.67	42.00B	447.02M	-1.18B	-906.14M	-6.1812

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-03-25	Initiated	Evercore ISI	Outperform
Aug-27-25	Upgrade	BofA Securities	Neutral → Buy
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight
Feb-21-23	Upgrade	Goldman	Neutral → Buy
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-14-22	Initiated	SVB Leerink	Outperform
Sep-09-22	Initiated	Morgan Stanley	Underweight
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-22-21	Downgrade	Goldman	Buy → Neutral
Jun-04-21	Resumed	Robert W. Baird	Neutral
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-05-20	Initiated	BofA Securities	Buy
Sep-14-20	Upgrade	Goldman	Neutral → Buy
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral
Aug-20-20	Initiated	Needham	Buy
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight
Mar-13-20	Downgrade	Goldman	Buy → Neutral
Feb-27-20	Downgrade	Robert W. Baird	Neutral → Underperform
Feb-04-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-19	Initiated	Robert W. Baird	Neutral
Nov-05-19	Initiated	Barclays	Overweight
Nov-05-19	Initiated	Cowen	Outperform
Nov-05-19	Initiated	Goldman	Buy
Nov-05-19	Initiated	JP Morgan	Overweight

View All

Vir Biotechnology Inc Stock (VIR) Latest News

03:05 AM

Norgine Pharmaceuticals Limited - AD HOC NEWS

03:05 AM

EQS-News: Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnologyboerse.de - boerse.de

03:05 AM

03:01 AM

Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology - PR Newswire

03:01 AM

Dec 16, 2025

Vir Biotechnology Licenses CHD Combination Therapy to Norgine for Europe, Australia, New Zealand - marketscreener.com

Dec 16, 2025

Vir Biotechnology issues license to Norgine to market hepatitis D candidate - Seeking Alpha

Dec 16, 2025

Vir Biotechnology Secures Licensing Deal with Norgine - TipRanks

Dec 16, 2025

Vir Biotechnology licenses hepatitis delta treatment to Norgine in €550m deal - Investing.com Canada

Dec 16, 2025

Vir Biotechnology licenses hepatitis delta treatment to Norgine in €550m deal By Investing.com - Investing.com South Africa

Dec 16, 2025

Vir Biotechnology (VIR) Secures Exclusive Licensing Deal with No - GuruFocus

Dec 16, 2025

Vir Biotechnology stock rises after licensing hepatitis delta treatment By Investing.com - Investing.com Canada

Dec 16, 2025

Vir Biotechnology grants Norgine exclusive commercial license to chronic hepatitis delta treatment candidate - marketscreener.com

Dec 16, 2025

Vir Biotechnology Grants Norgine Exclusive Commercial License To Chronic Hepatitis Delta Treatment Candidate - TradingView — Track All Markets

Dec 16, 2025

Vir Biotechnology signs agreement with Norgine for hepatitis Delta treatment - Traders Union

Dec 16, 2025

Vir Biotechnology grants Norgine exclusive license for hepatitis delta treatment - StreetInsider

Dec 16, 2025

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program - Business Wire

Dec 16, 2025

Dec 13, 2025

12,916,663 Shares in Vir Biotechnology, Inc. $VIR Bought by ARCH Venture Management LLC - MarketBeat

Dec 13, 2025

Dec 09, 2025

Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal By Investing.com - Investing.com Canada

Dec 09, 2025

Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal - Investing.com

Dec 09, 2025

Dec 08, 2025

After Losing 25% in the Past Year, Vir Biotechnology, Inc. (NASDAQ:VIR) Institutional Owners Must Be Relieved by the Recent Gain - 富途牛牛

Dec 08, 2025

Vir Biotechnology (VIR) Gains Positive Outlook Amid Industry Acq - GuruFocus

Dec 08, 2025

Vir Biotechnology (NASDAQ:VIR) Shares Gap UpShould You Buy? - MarketBeat

Dec 08, 2025

Vir Biotechnology Insiders Sold US$1.1m Of Shares Suggesting Hesitancy - simplywall.st

Dec 08, 2025

Dec 07, 2025

Can Vir Biotechnology (NASDAQ:VIR) Afford To Invest In Growth? - Yahoo Finance

Dec 07, 2025

Is Alnylam Pharmaceuticals a Millionaire Maker? - The Motley Fool

Dec 07, 2025

Dec 06, 2025

Is Vir Biotechnology Inc a good long term investmentRSI Overbought/Oversold & Rapid Wealth Accumulation - earlytimes.in

Dec 06, 2025

Dec 04, 2025

Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 191,854 Shares of Stock - MarketBeat

Dec 04, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 04, 2025

Dec 03, 2025

Insider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 22,000 Shares of Stock - MarketBeat

Dec 03, 2025